PARP inhibitors (PARPis), such as olaparib, talazoparib, rucaparib and niraparib, synergistically enhance PD-L1 blockade efficacy both in vitro and in vivo models [138,139,140,141] and are thus being evaluated in combination with ICIs in different cancer types [142,143,144]. The gene discussed is CD274; the disease is cancer.